Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This compound also downregulates expression of thymidylate synthase in vitro.

**Product Information**

**Product ID** L0360  
**CAS No.** 388082-78-8

**Chemical Name**

**Synonym**

**Formula** $\text{C}_{26}\text{H}_{26}\text{ClFN}_{4}\text{O}_{4}\text{S} \cdot 2\text{C}_{7}\text{H}_{8}\text{O}_{3}\text{S}$

**Formula Wt.** 925.46

**Melting Point** 236-259°C

**Purity** ≥98%

**Solubility** Slightly in DMSO

**Store Temp** 4°C

**Ship Temp** Ambient

**Description** Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This compound also downregulates expression of thymidylate synthase in vitro.

**References**


**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.

**Pricing and Availability**

**Bulk quantities available upon request**

<table>
<thead>
<tr>
<th>Product ID</th>
<th>Size</th>
<th>List Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>L0360</td>
<td>5 mg</td>
<td>$49.70</td>
</tr>
<tr>
<td>L0360</td>
<td>10 mg</td>
<td>$71.70</td>
</tr>
<tr>
<td>L0360</td>
<td>25 mg</td>
<td>$137.90</td>
</tr>
<tr>
<td>L0360</td>
<td>100 mg</td>
<td>$341.80</td>
</tr>
</tbody>
</table>

**Formula**

C$_{26}$H$_{26}$ClFN$_{4}$O$_{4}$S • 2C$_{7}$H$_{8}$O$_{3}$S

**CAS No.** 388082-78-8

**Store Temp** 4°C

**Ship Temp** Ambient